Ipamorelin for Menopause: What the Evidence Shows
What human and animal studies show about Ipamorelin for menopause, how strong that evidence is, and what is still unproven.
- Strongest evidence
- None graded
- no study with an outcome for menopause (PubMed search, 11 Oct 2026)
- Human studies
- 0
- PubMed records, our ledger
- Animal studies
- 0
- PubMed records, our ledger
Evidence for menopause
None of the study abstracts we summarised for Ipamorelin reported an outcome for menopause (PubMed search, 11 Oct 2026). Claims that it helps with menopause are unproven.
PubMed records for Ipamorelin and menopause: 0 human, 0 animal (search counts, not studies we reviewed).
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What menopause is
MedlinePlus defines menopause as the point after 12 months without a period, when pregnancy is no longer possible.[4]
MedlinePlus says menopause can cause you to lose bone density, which can lead to osteoporosis.[4]
No ipamorelin study has looked at menopause
The PubMed query pairing ipamorelin with menopause, hot flash, vasomotor or climacteric terms (run 2026-10-02) returned 0 human, 0 animal and 0 total records.
Calculated from human 0; animal 0; all 0. Formula: Counts copied from the ipamorelin ledger row of the menopause goal in goals.json; no arithmetic.
The nearest data, and why it is not menopause data
In adult female rats given ipamorelin by pump, bone mineral content rose on scans, but it did not rise once corrected for the extra body weight.[5]
In female rats given a glucocorticoid, simultaneous administration of ipamorelin counteracted the decrease in muscle strength and bone formation. This is animal data on steroid injury.[6]
In a human trial after bowel surgery, ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated.[7]
Standard care and class safety notes
MedlinePlus describes hormone therapy for menopause as another treatment for menopause symptoms.[4]
A clinical review of GH-axis peptides lists reported adverse effects including prolactin and cortisol elevations, appetite changes and dysglycaemia.[8]
Other peptides people research for menopause
All peptides for menopause, comparedCommon questions
Does ipamorelin help with menopause?
No study has tested it in menopause; the PubMed search returned 0 records.
Calculated from human 0; animal 0; all 0. Formula: Counts copied from the ipamorelin ledger row of the menopause goal in goals.json; no arithmetic.
Is Ipamorelin approved for menopause?
No. Ipamorelin is not FDA approved for any use, including menopause.
What is the best peptide for menopause?
There is no single answer. Our menopause overview compares each candidate by evidence grade and legal status rather than by popularity.
Can ipamorelin help with perimenopause symptoms?
No ipamorelin study in women is cited here. The rat bone study gave female rats ipamorelin continuously by pump for 12 weeks.[5]
More on Ipamorelin
Sources
- 1PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 4Official web pageOfficial web page · web page
- 5The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
- 6The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001PMID 11735244Accessed 2 Oct 2026
- 7Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 8The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
Found an error? Report a correction.